Global Markets
Gilead buys back China rights to ADC Trodelvy for $455m
Global MarketsGilead buys back China rights to ADC Trodelvy for $455mGilead buys back China rights to ADC Trodelvy for $455m
Everest Medicines has returned the rights for Trodelvy to a subsidiary of Gilead Sciences in an agreement worth up to $455 million.